NeuromodulationNCT05013827
Opinions of Company Representatives About Neuromodulation
An observational study of Neuromodulation and Pain, run by Moens Maarten at 1 site in Belgium.
Trial summary
The goal of this online survey is to gain further insight in the goals, expectations and definition of success for neuromodulation for pain, according to neuromodulation company representatives. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Neuromodulation, Pain, Survey
- What is being tested?
- Filling in an online survey
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 39 participants
- Where
- 1 siteBelgium
- Study dates
- 2 Sep 2021to 9 Sep 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain as company representatives will be eligible to complete the survey. The survey will be spread at the 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris from 2/9/2021 to 4/9/2021.
Who may be able to join
- Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain as company representatives will be eligible to complete the survey.
Who cannot join
- Not a company representative.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Opinions of Company Representatives About Neuromodulation for Pain: an Online Survey
The goal of this online survey is to gain further insight in the goals, expectations and definition of success for neuromodulation for pain, according to neuromodulation company representatives.
- Conditions
- Neuromodulation, Pain, Survey
- Being tested
- Filling in an online survey
- Medical subject headings
- Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Filling in an online surveyBehavioural
Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
| Study group | Role | What they receive |
|---|---|---|
| Company representatives | Not described Receives: Behavioral: Filling in an online survey |
What is being measured
The primary outcome is the main question the study is designed to answer.
Goals of company representatives, evaluated with a self-constructed question.
Goals of company representatives to treat patients with neuromodulation for pain.
Measured: Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.
Company representatives expectations, evaluated with a self-constructed question.
Factors that respondents expect to change according to neuromodulation for pain.
Measured: Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.
Company representatives definition of success of neuromodulation for pain, evaluated with a self-constructed question.
Company representatives their definition of success of neuromodulation for pain.
Measured: Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2021
- Study start2 Sep 2021
- Primary completion9 Sep 2021
- Study completion9 Sep 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NeuromodulationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 39 participants (actual)
Sponsor and investigators
- Lead sponsor
- Moens Maarten
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Moens Maarten, Universitair Ziekenhuis Brussel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05013827
- Sponsor's protocol ID
- OCEAN
- Status last verified
- Jan 2022
- First submitted
- 4 Aug 2021
- Last updated
- 14 Jan 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Opinions of Company Representatives About Neuromodulation for Pain: an Online Survey
- ClinicalTrials.gov ID
- NCT05013827
- Acronym / sponsor ID
- OCEAN
- Conditions
- Neuromodulation, Pain, Survey
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 39 participants (actual)
- Lead sponsor
- Moens MaartenUniversity, hospital or other
- Study start
- 2 Sep 2021 (actual)
- Primary completion
- 9 Sep 2021 (actual)
- Study completion
- 9 Sep 2021 (actual)
- First posted
- 19 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this online survey is to gain further insight in the goals, expectations and definition of success for neuromodulation for pain, according to neuromodulation company representatives.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Company representatives | – | Behavioral: Filling in an online survey |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain as company representatives will be eligible to complete the survey. The survey will be spread at the 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris from 2/9/2021 to 4/9/2021.
Key inclusion criteria (1 listed)
- Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain as company representatives will be eligible to complete the survey.
Key exclusion criteria (1 listed)
- Not a company representative.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Filling in an online surveyCompany representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain. | Behavioural | Company representatives |
Primary outcome
Goals of company representatives, evaluated with a self-constructed question.
Time frame: Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.
Goals of company representatives to treat patients with neuromodulation for pain.
Company representatives expectations, evaluated with a self-constructed question.
Time frame: Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.
Factors that respondents expect to change according to neuromodulation for pain.
Company representatives definition of success of neuromodulation for pain, evaluated with a self-constructed question.
Time frame: Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.
Company representatives their definition of success of neuromodulation for pain.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2022.
Related trials for Neuromodulation
RecruitingEarly Phase 1
Developing Transcranial Neuromodulation Protocols for Learning and Decision-Making
Normal Physiology
Not yet recruiting
Low-Intensity Focused Ultrasound for Gambling Disorder
Gambling Disorder, Gambling Addiction
Enrolling by invitation
Brain Stimulation Paired With Structured Reading Instruction in Children With Dyslexia
Dyslexia, Reading Disability
Not yet recruiting
SERENE Low-Intensity Focused Ultrasound for Cognitive Control
Suicidal Ideation, Cognitive Control
Recruiting
Transcutaneous Spinal Cord Stimulation Combined With 4-Aminopyridine and Intensive Rehabilitation in SCI
Spinal Cord Injuries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neuromodulation and Pain, run by Moens Maarten at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Goals of company representatives, evaluated with a self-constructed question. (time frame: Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2022.